Broader shield: can a 20-Valent vaccine outsmart pneumonia in babies?
NCT ID NCT07754539
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial evaluates an experimental vaccine called 20vPnC, designed to protect against 20 types of pneumococcal bacteria. Healthy infants aged 42 to 98 days will receive either 20vPnC or the approved 13vPnC vaccine at 2, 4, 6, and 12-15 months. The study aims to compare safety and immune responses between the two vaccines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 20-valent pneumococcal conjugate vaccine (20vPnC)
- What this could lead to
- If successful, this vaccine could offer broader protection against pneumococcal infections in infants, potentially reducing disease burden.
- What could go wrong
- The trial is in Phase 3 but results may not confirm superior efficacy or safety. Possible side effects include local reactions and systemic events.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
RECRUITINGNanning, Guangxi, 530021, China
-
Hezhou Center for Disease Control and Prevention
RECRUITINGHezhou, Guangxi, 542800, China
-
Wuming District Center for Disease Control and Prevention
RECRUITINGNanning, Guangxi, 530199, China
-
Zhongshan County Center for Disease Control and Prevention
RECRUITINGZhongshan Town, Guangxi, 542600, China